Abstract
EBV-associated HD and NHL show type II latency expressing subdominant EBV antigens such as LMP2, which may serve as targets for immunotherapy. Previously, we used polyclonal EBV-specific CTL in patients with relapsed EBV +ve HD and saw 2 CRs and 1 PR in 11 patients. We now hypothesize that CTL specifically targeting LMP2 might have greater efficacy. LMP2-CTL were generated using dendritic cells and lymphoblastoid cell lines which had been genetically modified to overexpress LMP2 by transduction with an Ad5f35LMP2 vector.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
